MedTrace Logo

Copeptin in Differentiation of Polyuria and Polydipsia

NCT01056887 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2011-04-25

No results posted yet for this study

Summary

The differential diagnosis of patients with polyuria/ polydipsia is often complex, but important for the therapeutic strategy.

Challenging is in particular the clinical differentiation between patients with a partial Diabetes insipidus centralis and patients with primary polydipsia as underlying disease, because both groups are associated with similar urinary osmolalities.

The determination of plasma arginine vasopressin is unusual in this context, since measurement of AVP is not reliably.

C-terminal ProVasopressin (copeptin) is secreted stoichiometrically with AVP from the neurohypophysis, but has a longer half life in the circulation, and is thus easier to measure.

Therefore, the investigators will analyze in that study the diagnostic utility of plasma copeptin in the differential diagnosis of polyuria and polydipsia.

Conditions

  • Polyuria
  • Polydipsia

Sponsors & Collaborators

  • Dr. Carson Liu Med Corp.

    collaborator INDUSTRY

  • University of Wuerzburg

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01056887 on ClinicalTrials.gov